The prodrug is rationallydesigned to have numerous layers of pancreatic cancer targeting viathe tumor-selective overexpression of the key β-lapachone activatingenzymes NQO1 and 5-LO, the TME expression pattern of the release-triggeringenzyme β-glucuronidase, and the opportunity for modular attachmentto carrier systems targeting pancreatic cancer membrane proteins.Various derivatives of this prodrug have shown promising stability,release, and efficacy against pancreatic cancer cell lines. The gene discussed is NQO1; the disease is familial pancreatic carcinoma.